Archive for the ‘market’ tag

Research and Markets: Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)

without comments

Research and Markets has announced the addition of the “Osteoporosis Drug Market- Global And China Market Analy

Original post:
Research and Markets: Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)

Written by admin

February 2nd, 2012 at 9:49 pm

Global Osteoporosis Market is Expected to Attain a Market Size of USD 6.8 billion in 2015, China Osteoporosis Market …

without comments

ALBANY, New York, January 31, 2012 /PRNewswire/ —

According to a new report published by Transparency Market Research (http://www.transparencymarketresearch.com) “Osteoporosis Drug Market- Global and China market analysis, size, trends and forecast (2010-2015)” Global Osteoporosis Market is estimated to be USD 7.3 billion in 2010 and expected to reach USD 11.4 billion in 2015 at a CAGR of 9.2% over the period 2010 to 2015. Bisphosphonate segment accounted for the largest share at 62.0% of weight management market in 2010. China Osteoporosis market will be worth USD 2.5 billion in 2015.

Browse full report at:   http://www.transparencymarketresearch.com/osteoporosis-drug-market.html

In 2009, the Global Osteoporosis Drug Market was worth USD 6.8 billion, with Bisphosphonate class of drugs leading the market. In the overall Bisphosphonate, ibandronate (Bonviva/Boniva; Roche) and zoledronate (Aclasta/Zometa; Novartis) accounted healthy market share and showed an average sales growth rate of about of 20% in the past 2 years.

Amgen's Denosumab is the recent entrant to the Osteoporosis treatment market, following its approval from the U.S. and European Union (also approved for bone loss associated with prostate cancer). Denosumab is expected to compete directly with the Bisphosphonate drug class. However, initial uptake of Denosumab is likely to be as second-line therapy, mostly in patients who are intolerant to Bisphosphonate. In addition to the treatment of Osteoporosis, there is substantial potential for Denosumab for treating bone loss in patients with cancer. Denosumab market is expected to reach USD 3.8 billion in 2015.

Our research indicates that the Osteoporosis drug pipeline is going strong with various phases of clinical development. Phase III has first-in-class products such as odanacatib, which possess a novel mechanism of action to combat Osteoporosis. Aprela is another drug in the stage of development.

The Chinese Osteoporosis drug market is expected to grow at a CAGR of 13.5% from 2010 to 2015. Increased prevalence of Osteoporosis among Chinese female population is the principal growth driver of the Osteoporosis drug market. The other key growth drivers for Chinese Osteoporosis market include increasing elderly aged population, rising living standards of the Chinese people and increasing awareness and bone health education.

To gain a competitive advantage, market players should develop cost-competitive drugs with easy dosage pattern, which promote bone building effectively. Large numbers of patients are unable to comply with the strict dosage schedule of traditional Osteoporosis drugs. Further research and development can address the unmet need by coming up with drugs that have a convenient dosage schedule with better efficacy and safety compared to traditional treatment of Osteoporosis.

This report provides in-depth analysis of global and China Osteoporosis Market based on following segmentation:

By Segment Bisphosphonate Drugs SERM Drugs Parathyroid Hormone Drugs Calcitonin Drugs Denosumab Drugs

Related & Recently Published Reports by Transparency Market Research

Weight Loss Market

Energy Efficient Lighting Technology Market

Energy Efficient Lamps Market

Diabetes Devices Market

Drug Eluting Stents Market

Cardiovascular Devices Market

Baby Food Market

Minimally Invasive Surgery Market

Browse all Pharmaceutical Market  Research Reports

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Ms Amita
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
http://www.transparencymarketresearch.com/
http://www.twease.org/
http://blog.transparencymarketresearch.com/
http://transparencymarketresearch.blogspot.com/

Link:
Global Osteoporosis Market is Expected to Attain a Market Size of USD 6.8 billion in 2015, China Osteoporosis Market …

Written by admin

February 1st, 2012 at 6:43 am

Research and Markets: Women's Health Therapeutics Market to 2017 – High Unmet Need will Drive Uptake of Novel Drugs

without comments

Research and Markets has announced the addition of the “Women's Health Therapeutics Market to 2017 – High Unme

Link:
Research and Markets: Women's Health Therapeutics Market to 2017 – High Unmet Need will Drive Uptake of Novel Drugs

Written by admin

January 11th, 2012 at 3:38 pm

Women’s Health Therapeutics Market to 2017 – High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and …

without comments

NEW YORK , Jan. 4, 2012 /PRNewswire/ – Reportlinker.com announces that a new market research report is available in its catalogue: Women’s Health Therapeutics Market to 2017 – High Unmet Need will Drive …

Read more from the original source:
Women’s Health Therapeutics Market to 2017 – High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and …

Written by admin

January 4th, 2012 at 10:45 am

Best HGH product – Video

without comments


Best HGH product – link to online store rxdrughost.com Growth Hormone 250mg bottles Certified Natural High Potency HGH is the ultimate HGH hormone replacement therapy in a bottle. The first class quality of Growth Hormone best hgh product altitude best hgh product off the market best hgh…

Continued here:
Best HGH product – Video

Written by admin

December 31st, 2011 at 6:33 am

Best Natural Hgh Human Growth Hormone Releasers – Video

without comments


www.growth-rx.com Casey The Supplement Guy does An Amazing review of the top natural Hgh supplement pills on the market. Which Hgh enhancers are right for you and WHY?

Continued here:
Best Natural Hgh Human Growth Hormone Releasers – Video

Stem cell therapy poised to shake-up medicine as dozens of clinical trials show early success

without comments

Dozens of adult stem cell treatments are moving through clinical trials and showing early success, raising hopes that some could reach the market within five years.

Read more:
Stem cell therapy poised to shake-up medicine as dozens of clinical trials show early success

Stem cell therapy poised to come in from the cold

without comments

After years of mishaps, stem cell treatments are moving through clinical trials and showing early success, raising hopes that some could reach the market within five years.

Follow this link:
Stem cell therapy poised to come in from the cold

Research and Markets: Postmenopausal Osteoporosis Therapeutics – Pipeline Assessment and Market Forecasts to 2017

without comments

Research and Markets has announced the addition of GlobalData’s new report “Postmenopausal Osteoporosis Therapeutics – Pipeline Assessment and Market Forecasts to 2017″ to their offering.

Link:
Research and Markets: Postmenopausal Osteoporosis Therapeutics – Pipeline Assessment and Market Forecasts to 2017

Bisphosphonate Osteoporosis Drugs: FDA Questions Long-term Effects

without comments

Biphosphonates, drugs introduced to the market 16 years ago that treats osteoporosis, need labeling to clarify how long patients should take them as data suggests that efficacy decreases while risk increases after some period, panels to the Food and Drug Administration (FDA) voted on Friday.

See more here:
Bisphosphonate Osteoporosis Drugs: FDA Questions Long-term Effects

Written by admin

September 11th, 2011 at 8:19 pm







Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research